Tomoko Funazo

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji et al. · Scientific Reports · 2017 · 117 citations · Full text

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki et al. · Nature Communications · 2020 · 80 citations · Full text

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki et al. · Molecular Cancer Research · 2018 · 47 citations · Full text

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim et al. · Cell Death and Disease · 2020 · 47 citations · Full text

Nivolumab in non-small-cell lung cancer with EGFR mutation

Hironori Yoshida, Y.H. Kim, Hiroaki Ozasa et al. · Annals of Oncology · 2017 · 35 citations · Full text